

15. 辻本豪三. 【薬理遺伝学の最近の進歩】 総論 加速化する個の医療 最近の薬理遺伝学の進歩. *BIO Clinica* 2007;22:1236-1238.

16. 横井治彦, 水上民夫. Pharmacogenomics for cancer Therapy 個別化医療に向けたFDAのイニシアティブ ファーマコゲノミクス関連ガイダンスを中心に. *がん分子標的治療* 2007;5:50-57.

17. FDA. Celebrating the two-year milestone and planning for the future of voluntary genomic data submissions (VGDS) to the FDA, [online]. Available at: <http://www.fda.gov/cder/genomics/presentations.htm>.

18. 日本産科婦人科学会 [online]. Available at: <http://www.jsog.or.jp/>.

19. 川口恵子. 【女性のライフサイクルと漢方】 私はこうしている HRTと漢方. *産婦人科治療* 2004;89:449-451.

20. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The women's health initiative memory study: A randomized controlled trial. *JAMA* [serial online] 2003;289:2651-62.

21. 生殖・内分泌委員会. 婦人科 60 巻 6 号 (専門委員会報告) [online]. Available at:

[www.jsog.or.jp/activity/pdf/seishokunaibunpitsu\\_vol60no6.pdf](http://www.jsog.or.jp/activity/pdf/seishokunaibunpitsu_vol60no6.pdf).

22. 寺澤捷年. 症例から学ぶ和漢診療学. 医学書院, .

23. 天野恵子. 性差医療. 真興交易 (株) 医書出版部, 2005 年.

24. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. *Endocrinology* [serial online] 1997;138:863-70.

25. Geng Y. Comparison of the polymorphisms of androgen receptor gene and estrogen alpha and beta gene between adolescent females with first-onset major depressive disorder and controls. *International journal of neuroscience* [serial online] 2007;117:539-47.

26. McIntyre MH. Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms. *Cancer epidemiology biomarkers prevention* [serial online] 2007;16:2233-6.

27. Setiawan VW. Estrogen receptor beta (ESR2) polymorphisms and endometrial cancer (united states). *Cancer causes control* [serial online] 2004;15:627-33.

28. Tsezou A. Association of repeat polymorphisms in the estrogen receptors alpha, beta (ESR1, ESR2) and androgen receptor (AR) genes with the occurrence of breast cancer. *The Breast* [serial online] 2008;17:159-66.

29. Geng L. Association of CA repeat polymorphism in estrogen receptor beta

gene with postmenopausal osteoporosis in chinese. 遗传学报 [serial online] 2007;34:868-76.

30. Ashworth JJ. The dinucleotide (CA) repeat polymorphism of estrogen receptor beta but not the dinucleotide (TA) repeat polymorphism of estrogen receptor alpha is associated with venous ulceration. The Journal of steroid biochemistry and molecular biology [serial online] 2005;97:266-70.

31. Rexrode KM. Polymorphisms and haplotypes of the estrogen receptor-beta gene (ESR2) and cardiovascular disease in men and women. Clinical Chemistry [serial online] 2007;53:1749-56.

32. Gennari L, Merlotti D, De Paola V, et al. Estrogen receptor gene polymorphisms and the genetics of osteoporosis: A HuGE review. American journal of epidemiology [serial online] 2005;161:307-20.

33. 川口恵子. 【中高年女性のQOL向上を目指して】 HRTと漢方. 産婦人科治療 2006;93:71-75.

34. Pan B. Treatment of climacteric symptoms with herbal formulas of traditional chinese medicine. Gynecologic and obstetric investigation [serial online] 2004;57:144-8.

35. Kwee SH. The effect of chinese herbal medicines (CHM) on menopausal symptoms compared to hormone replacement therapy (HRT) and placebo. Maturitas [serial online] 2007;58:83-90.

36. Ushiroyama T, Hosotani T, Mori K, Yamashita Y, Ikeda A, Ueki M. Effects of switching to wen-jing-tang (unkei-to) from preceding herbal preparations selected by eight-principle pattern identification on endocrinological status and ovulatory induction in women with polycystic ovary syndrome. The American journal of Chinese medicine [serial online] 2006;34:177-87.

37. Chung MH, Suzuki S, Nishihara T, Hattori M. Estrogenic effects of a kampo formula, tokishakuyakusan, in parous ovariectomized rats. Biological Pharmaceutical Bulletin [serial online] 2008;31:1145-9.

38. Yukie Kumagai SH. Estrogen-like activity in kampo medicines used for menopausal symptoms and gynecological disease. J Trad Med 2005;22:228-236.

39. Koji Watanabe SH. Agonistic or antagonistic action of kampo medicines used for menopausal symptoms on estrogen receptor subtypes, ER $\alpha$  and ER $\beta$ . J Trad Med 2006;23:203-207.

40. Guidelines for counseling postmenopausal women about preventive hormone therapy. american college of physicians. Annals of internal medicine [serial online] 1992;117:1038-41.